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Maternal nutrition and growth hormone (GH) treatment during early- to mid-pregnancy can each alter the subsequent growth and differ-
entiation of muscle in progeny. We have investigated the effects of varying maternal nutrition and maternal treatment with porcine (p) GH
during the second quarter of pregnancy in gilts on semitendinosus muscle cross-sectional area and fibre composition of progeny, and
relationships between maternal and progeny measures and progeny muscularity. Fifty-three Large White £ Landrace gilts, pregnant to
Large White £ Duroc boars, were fed either 2·2 kg (about 35 % ad libitum intake) or 3·0 kg commercial ration (13·5 MJ digestible
energy, 150 g crude protein (N £ 6·25)/kg DM)/d and injected with 0, 4 or 8 mg pGH/d from day 25 to 50 of pregnancy, then all were
fed 2·2 kg/d for the remainder of pregnancy. The higher maternal feed allowance from day 25 to 50 of pregnancy increased the densities
of total and secondary fibres and the secondary:primary fibre ratio in semitendinosus muscles of their female progeny at 61 d of age post-
natally. The densities of secondary and total muscle fibres in semitendinosus muscles of progeny were predicted by maternal weight before
treatment and maternal plasma insulin-like growth factor-II during treatment. Maternal pGH treatment from day 25 to day 50 of pregnancy
did not alter fibre densities, but increased the cross-sectional area of the semitendinosus muscle; this may be partially explained by
increased maternal plasma glucose. Thus, maternal nutrition and pGH treatment during the second quarter of pregnancy in pigs indepen-
dently alter muscle characteristics in progeny.
Pregnancy: Programming: Muscle: Pig
Maternal nutrition and other factors affecting the fetal
environment cause permanent changes in, or programme,
postnatal growth and body composition in multiple species,
including human subjects (Barker, 1998; Martorell et al.
2001), rats, pigs (Dwyer et al. 1994) and sheep (Greenwood
et al. 1995). While few intra-uterine programming mechan-
isms have been identified, it is proposed that the environment
in which critical developmental processes occur permanently
determines phenotype (Lucas, 1991). Programming of post-
natal growth and composition by an adverse intra-uterine
environment is associated with increased risk of adult disease
(Barker, 1998). We have investigated in pigs the effects on
postnatal skeletal muscle structure and composition of
manipulating the maternal, and hence fetal, environment
during pregnancy at a critical stage of fetal muscle
development.
In pigs, primary muscle fibres (peripheral myofibres,
axial nuclei) form between day 35 and 60 of gestation
(term about 115 d), whilst secondary fibres (axial myofi-
bres, peripheral nuclei) form between day 54 and 90 of
gestation (Ashmore et al. 1973; Wigmore & Stickland,
1983). Maternal undernutrition during the period of sec-
ondary muscle fibre development in the fetus reduces the
numbers of total and secondary muscle fibres in pigs
(Dwyer et al. 1994), as also occurs in guinea-pigs (Ward
& Stickland, 1991; Dwyer et al. 1995) and rats (Howells
et al. 1978; Bedi et al. 1982; Wilson et al. 1988). In
mature sows, maternal undernutrition prior to the period
of secondary muscle fibre development in the fetus also
reduces the number of secondary muscle fibres in their pro-
geny, and the effect of maternal nutrition on muscle fibre
numbers is seen in small but not large littermates (Dwyer
* Corresponding author: Dr Kathryn L. Gatford, fax +61 8 8303 3356, email kathy.gatford@adelaide.edu.au
† Present address: California Regional Primate Research Center, University of California, Davis, CA, USA.
‡ Present address: Tamworth Centre for Crop Improvement, NSW Agriculture, Tamworth, NSW, 2340, Australia.
§ Present address: Ausgene, P. O. Box 427, Gridley, IL, USA.
Abbreviations: GH, growth hormone; IGF, insulin-like growth factor; p, porcine.
British Journal of Nutrition (2003), 90, 283–293 DOI: 10.1079/BJN2003893
q The Authors 2003
et al. 1994). The effects of maternal nutrition might be
expected to be more significant in the primiparous sow
(gilt) where maternal growth increases the competition
for available nutrients. The effect of maternal nutrition in
pregnant gilts on progeny muscle development has not
been reported, however. Formation of primary muscle
fibres appears to be less susceptible to changes in the
maternal environment, or to spontaneous restriction of
fetal growth, than that of secondary fibres (Wigmore &
Stickland, 1983; Handel & Stickland, 1987; Ward &
Stickland, 1991; Dwyer et al. 1994).
Growth hormone (GH) is structurally similar to hor-
mones secreted by the placenta during pregnancy (placen-
tal lactogen, placental GH variant), and treatment of pigs
with GH mimics the increased insulin resistance character-
istic of pregnancy (Walton & Etherton, 1986; Gopinath &
Etherton, 1989). Fetal growth is promoted by maternal GH
treatment during pregnancy in rats and in pigs (Spencer
et al. 1994; Kelley et al. 1995; Sterle et al. 1995; Gatford
et al. 2000), and in rats maternal GH treatment during
pregnancy also programmes increased postnatal growth
of progeny (Spencer et al. 1994). Programming of sub-
sequent fetal and postnatal growth by maternal GH treat-
ment for only part of pregnancy in pigs varies with
maternal nutrition, the duration and timing of treatments
and dose of GH administered (Kveragas et al. 1986;
Kirkwood et al. 1993; Rehfeldt et al. 1993; Kelley et al.
1995). In well-fed pigs, increased muscle growth and sec-
ondary muscle fibre numbers in postnatal progeny can be
programmed by maternal treatment with porcine (p) GH
during early- to mid-pregnancy, before the period of sec-
ondary muscle fibre formation (Rehfeldt et al. 1993,
1996; Kelley et al. 1995). Whether maternal GH treatment
also programmes progeny muscle phenotype in restricted-
fed gilts is unknown.
In the present study, we have used maternal nutrition and
GH treatment to manipulate maternal metabolism and
hence the fetal environment in the pig. We have shown
previously that pGH treatment of the commercially main-
tained (i.e. feed-restricted) gilt between days 25 and 50
of pregnancy increases fetal body weight and size, prob-
ably due to greater availability of maternal substrates and
hence increased fetal nutrient supply (Gatford et al.
2000). We hypothesised that increased maternal nutrition
or maternal pGH treatment during early- to mid-pregnancy
in feed-restricted gilts would increase the secondary
muscle fibre numbers and postnatal growth rates of their
progeny. We also investigated the relationships between
progeny muscle outcomes and markers of maternal and
progeny growth and metabolism as indicators of the poten-




The present study was designed in accordance with the Aus-
tralian Code of Practice for the Care and Use of Animals
for Scientific Purposes (National Health and Medical
Research Council of Australia, 1997) and approved by
the Animal Experimentation Ethics Committee of Bunge
Meat Industries (Corowa, New South Wales, Australia).
Fifty-three Large White £ Landrace gilts were bred at
first oestrus to crossbred (Large White £ Duroc) boars.
Gilts were fed 2·2 kg ration (13·5 MJ digestible energy
and 150 g crude protein (N £ 6·25)/kg DM)/d (about 35 %
ad libitum intake in this genotype) throughout pregnancy,
except that from the day 25 to 50 of pregnancy, half
(twenty-seven gilts) were fed 3·0 kg of the same ration/d.
Gilts were fed the diets shown in Table 1 at 07.00 hours
daily. From day 25 to 50 of pregnancy, gilts on both
ration rates also received daily intramuscular injections at
about 10.00 hours of 1 ml sterile water in the neck
region, containing 0, 4 or 8 mg pGH (recombinant pGH;
Southern Cross Biotech Pty Ltd, Melbourne, Victoria,
Australia), which delivered average dose rates of pGH
across the treatment period of 0·0, 26·7 (SEM 0·5), or 53·1
(SEM 0·6)mg/kg (six to eleven dams per group). Gilts
were bled by jugular venepuncture at about 13.00 hours
on day 40 of pregnancy and EDTA-plasma was stored at
2208C. Gilts delivered naturally at term. Within 12 h of
birth, litter size and individual piglet body dimensions
were measured and each piglet was identified by ear-tag-
ging. Litter size was equalised by fostering piglets within
treatment group at this time. A single female of median
birth weight for her litter was selected at weaning (27 d
of age) for analysis of the effects of maternal treatments
on progeny muscle development. A single gender was
selected to remove confounding effects of progeny gender
Table 1. Composition of maternal diets (g/kg) during pregnancy
and lactation
Analysis* Pregnancy diet Lactation diet
Digestible energy (MJ DE/kg) 14·5 14·5


















Aspartic acid 12·8 17·0
Glutamic acid 33·0 37·5
Vitamin and mineral premix† 1·5 1·5
DE, digestible energy.
* From Format database, Bunge Meat Industries Ltd (Corowa, New South
Wales, Australia).
† Vitamin and mineral contents (per kg mixed feed): Vitamin A 5·1mg,
Vitamin D3 0·05mg, Vitamin E 60 mg, Vitamin K 2 mg, folic acid 0·5 mg,
niacin 10 mg, calcium-D-pantothenate 5 mg, riboflavin 3·5 mg, vitamin B6
(pyridoxine) 2 mg, vitamin B12 (cyanocobalamin) 0·02 mg, biotin 0·2 mg,
selenium 0·3 mg, copper 20 mg, iron 80 mg, manganese 40 mg, zinc
75 mg, iodine 1 mg, betaine 100 mg, antioxidant (ethoxyquin, Endox,
Kemin Pty Ltd, Sydney, NSW, Australia) 100 mg.
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from the analysis. Females were selected because their
muscularity and live-weight gains are less than those of
males and hence have a greater potential to show responses
to treatments. The median-birth-weight progeny were each
weighed at 27·2 (SEM 0·3), 34·2 (SEM 0·3) and 60·8 (SEM
0·6) d postnatal age. Pigs were then killed at 60·8 (SEM
0·6) d of age by injection of 20 ml pentobarbitone sodium
(325 g/l; Lethabarb, Virbac (Aust.) Pty, Ltd, Peakhurst,
New South Wales, Australia) into an ear vein. The semiten-
dinosus muscle was immediately dissected and a section
(about 15 mm thick) was cut perpendicular to the fibre
direction midway along the muscle. A tracing was made
of the section to determine its area. It was then subdivided
into three to six pieces, comprising the entire area of the
cross-section, so that sections of each piece would fit
onto a single slide for staining. Each piece was embedded
in Optimal Cutting Temperature (OCT) medium (Tissue
Tek, Sakura Finetechnical Co. Ltd, Tokyo, Japan) and
frozen flat in isopentane, cooled in liquid N2, placed on
dry ice, and then stored at 2808C prior to analysis.
Analysis of maternal metabolites and hormones
Plasma concentrations of glucose (GLUC HK, Roche
Diagnostic Systems, Mannheim, Germany), urea (UREA;
Roche Diagnostic Systems), non-esterified fatty acids
(NEFA C; Wako Pure Chemicals, Osaka, Japan), triacyl-
glycerol (TRIG; Roche Diagnostic Systems), lactate
(LACT MPR1; Boehringer Mannheim, Mannheim,
Germany) and cholesterol (CHOL; Roche Diagnostic Sys-
tems) were measured by enzymatic analysis. Plasma a-
amino-N concentrations were measured by colorimetric
assay (Evans et al. 1993). Insulin was measured using a
commercial radioimmunoassay (Insulin CT kit; CIS Bio
International, Cedex, France). Insulin-like growth factor
(IGF)-I and -II were separated from binding proteins by
size-exclusion HPLC of plasma at pH 2·5 (Owens et al.
1990). IGF-I and -II were then determined in neutralised
chromatography fractions by specific radioimmunoasssay
(Francis et al. 1989; Carr et al. 1995).
Analysis of muscle fibres
Tracings of muscle sections were scanned and their areas
measured (n 53 progeny) using Sigma Scan Pro software
(Jandel Scientific Software, San Rafael, CA, USA). Sec-
tions (10mm thick) were cut by cryostat from each piece
of the semitendinosus muscle of each pig (three to six
pieces per animal, comprising the entire cross-sectional
area of the muscle for each pig), and mounted on plain
glass slides. Differentiation of primary and secondary
fibre types (Guth & Samaha, 1970) in porcine semitendino-
sus muscle was obtained by staining consecutive sections
at pH 10·4 and 4·3 for alkali-stable and acid-stable acto-
myosin ATPase respectively (n 43 progeny). Fibres were
counted in either the alkali- or acid-stained section,
chosen for ease of fibre type differentiations. Each cluster
of dark-stained fibres in acid-stable stained sections, or
light-stained fibres in alkali-stained sections, was desig-
nated as containing one primary fibre. The total number
of fibres and the number of primary fibres were counted
in each field. For each slide, the total number of muscle
fibres and the number of primary fibres were counted in
twenty microscope fields (field area 0·4345 £ 1026 m2),
viewed at £ 20 magnification, which was equivalent to
about 5 % of the muscle area. An initial field containing
a clean transverse section (approximately circular fibre
cross-sections) was selected randomly, and subsequent
fields were selected by moving stepwise in 1 mm incre-
ments. Fields containing ellipsoid fibre cross-sections, indi-
cating a non-transverse section, were excluded, and another
field chosen. Areas of large blood vessels and perimysial
connective tissue were excluded from analysis. Total and
primary fibres (n per field) were calculated as means of
measurements made from three to six sections for each
animal. Secondary muscle fibres (n per microscope field)
were calculated by difference between total and primary
fibre number. Mean number of total, primary and second-
ary fibres per mm2 (muscle fibre density) and the mean
secondary fibres:primary fibres ratio were calculated for
each animal.
Statistics
Results are presented as arithmetic mean values with their
standard errors (n is the number of dams or progeny).
Effects of maternal nutrition and maternal pGH treatment
during pregnancy were assessed by two-way ANOVA.
Data were transformed to achieve equivalent variance
and normal distribution before ANOVA where appropriate,
as indicated in the Table footnotes and Figure legends.
Pairwise multiple comparisons were made using the
Student–Newman–Keuls method. Associations between
measurements were identified by Pearson correlation for
normally distributed variables, and by Spearman’s r corre-
lation for variables that were not normally distributed.
Independent covariates were identified by forward stepwise
linear regression and confirmed by multiple linear
regression (SigmaStat V1; Jandel Scientific Software).
Results
Maternal responses
Maternal weight at day 25 of pregnancy (139·8 (SEM
1·3) kg) did not differ between treatment groups. Sows
fed 3 kg/d gained more weight from day 25 to 50 of preg-
nancy in absolute (Table 2, P,0·001) and fractional (2 kg
feed/d, 11·6 (SEM 0·7) %; 3 kg feed/d, 17·2 (SEM 0·7 %;
P,0·001) terms than sows fed 2·2 kg/d. Maternal pGH
treatment did not affect absolute weight gain from day
25 to 50 of pregnancy (Table 2), but tended to increase
fractional weight gain from day 25 to 50 of pregnancy
(0 mg pGH/d, 13·8 (SEM 0·8) %; 4 mg pGH/d, 15·9 (SEM
0·8) %; 8 mg pGH/d, 13·5 (SEM 0·9) %; P¼0·099). Sows
treated with pGH lost backfat depth from day 25 to 50 of
pregnancy (P¼0·002) and increased maternal feed level
tended to decrease loss of backfat from day 25 to 50 of
pregnancy (P¼0·081, Table 2). Increased maternal nutri-
tion increased the insulin:glucose ratio (P¼0·044)
and plasma cholesterol concentration (P¼0·050), and
tended to increase the concentrations of urea (P¼0·093),
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triacylglycerol (P¼0·058) and insulin (P¼0·068) in
maternal plasma at day 40 of pregnancy (Table 2).
Maternal pGH treatment increased the concentrations of
glucose (P,0·001), non-esterified fatty acids (P¼0·029),
insulin (P¼0·006) and IGF-I (P¼0·031), and tended to
increase the concentration of cholesterol (P¼0·053) and
insulin:glucose ratio (P¼0·079) in maternal plasma
(Table 2). Maternal pGH treatment also decreased the
concentration of urea (P,0·001) in maternal blood
(Table 2). Maternal plasma concentrations of a-amino-N,
lactate and IGF-II were unaffected by maternal nutrition
or pGH treatment (Table 2).
Overall, the absolute maternal weight-gain from day 25 to
50 of pregnancy correlated positively with maternal plasma
concentrations of cholesterol (r þ0·36, P¼0·020) at day 40
of pregnancy. The fractional maternal weight gain from day
25 to 50 of pregnancy was also correlated positively with
maternal plasma concentrations of cholesterol (r þ0·44,
P¼0·004) and lactate (r þ0·33, P¼0·038). The absolute
change in maternal backfat depth from day 25 to 50 of preg-
nancy correlated positively with the absolute (r þ0·36,
P¼0·007) and fractional (r þ0·39, P¼0·004) maternal
weight gains from day 25 to 50 of pregnancy. The absolute
change in maternal backfat depth from day 25 to 50 of preg-
nancy also correlated positively with maternal plasma
concentration of urea (r þ0·43, P¼0·005). Maternal
plasma glucose concentrations correlated positively with
maternal plasma concentrations of non-esterified fatty
acids (r þ0·43, P¼0·006), insulin (r þ0·53, P,0·001),
cholesterol (r þ0·31, P¼0·045), IGF-I (r þ0·33,
P¼0·034) and the insulin:glucose ratio (r þ0·34,
P¼0·029). In addition, on day 40 of pregnancy, maternal
plasma concentrations of urea (r þ0·50, P¼0·001) and
lactate (r þ0·37, P¼0·020) were correlated positively
with maternal plasma IGF-II. Maternal plasma concen-
trations of triacyglycerol and non-esterified fatty acids
were positively correlated with each other (r þ0·51,
P¼0·001), as were maternal plasma concentrations of
cholesterol and lactate (r þ0·39, P¼0·012).
Progeny birth phenotype and postnatal growth
Litter size (n 9·96 (SEM 0·32)), live piglets born per litter (n
9·49 (SEM 0·30)) and average body weight of live newborn
piglets per litter (1·51 (SEM 0·03) kg) were unaffected by
maternal treatments. Similarly, the body weight (1·55
(SEM 0·3) kg), length (397 (SEM 3) mm) and abdominal cir-
cumference (257 (SEM 3) mm) of selected progeny at birth
were not altered by maternal nutrition or pGH treatment.
Increased maternal nutrition, but not pGH, from day 25
to 50 of pregnancy tended to increase (P¼0·07) biparietal
diameter of selected progeny at birth (2·2 kg/d, 45·4 (SEM
0·3) mm; 3·0 kg/d, 46·2 (SEM 0·3) mm). Higher feed
intake by gilts during the second quarter of pregnancy
also increased the live weight of selected progeny at 27 d
of age (2·2 kg/d, 6·76 (SEM 0·33) kg; 3·0 kg/d, 7·70 (SEM
0·35) kg; P¼0·040). Maternal nutrition did not affect
weight of selected progeny at 34 d of age (8·13 (SEM
0·26) kg, P¼0·17) or at 61 d of age (22·62 (SEM 0·75) kg,
P¼0·97). Maternal pGH treatment from day 25 to 50 of
pregnancy did not alter progeny weight at any age or
growth rate for any postnatal period examined. Increased
maternal nutrition from day 25 to 50 of pregnancy
increased the rates of gain in body weight of selected
progeny from birth to 27 d of age in absolute (2·2 kg/d,
0·195 (SEM 0·011) kg/d; 3·0 kg/d, 0·224 (SEM 0·010) kg/d;
P¼0·05) but not fractional terms (P¼0·23). Absolute and
fractional post-weaning growth rates were unaffected by
maternal nutrition or pGH treatment. Growth rates aver-
aged 0·114 (SEM 0·016) kg/d between 27 and 34 d of age,
0·538 (SEM 0·018) kg/d between 34 and 61 d of age and
0·344 (SEM 0·010) kg/d between birth and 61 d of age.
Body weight of selected progeny at birth correlated posi-
tively and strongly with body length, biparietal diameter
and abdominal circumference at birth (r . þ0·69 for all,
P,0·0001 for all). Live weights at 27 and at 34 d of age
were also correlated positively with body weight at birth
(27 d, r þ0·33, P¼0·018; 34 d, r þ0·28, P¼0·045) and
body length at birth (27 d, r þ0·30, P¼0·029; 34 d, r
þ0·32, P¼0·020). Live weight at 61 d of age was not
related to birth weight, but correlated positively with
birth length (r þ0·32, P¼0·021). Fractional growth rates
from birth to 27 d of age (r 20·37, P¼0·007) and from
birth to 61 d of age (r 20·45, P,0·001) were correlated
negatively with birth weight.
Progeny semitendinosus muscle size and muscle fibre types
Maternal pGH treatment during the second quarter of preg-
nancy increased the cross-sectional area of the semitendino-
sus muscle in progeny at 61 d of age (ANOVA P¼0·028;
Fig. 1), such that cross-sectional area was increased in pro-
geny of sows treated with 4 mg/d relative to progeny of sows
treated with 0 mg pGH/d (P,0·05). However, the semiten-
dinosus cross-sectional area relative to current live weight
(mm2/kg) was not increased by maternal pGH treatment
(P¼0·1). Maternal pGH treatment during the second quarter
of pregnancy did not affect the total number of fibres or the
Fig. 1. Effects of maternal treatments on semitendinosus muscle
size and fibre density in 61-d-old female progeny. Primiparous
sows received feed and porcine (p) growth hormone (GH) treat-
ments from day 25 to 50 of pregnancy, when they were fed at either
2·2 (†) or 3·0 (W) kg/d. For details of diets, treatments and pro-
cedures, see Table 1 and p. 284. Values are means with their stan-
dard errors shown by vertical bars. Cross-sectional area data were
log-transformed for statistical analyses to remove non-equivalent
variances. The cross-sectional area of semitendinosus muscle in
61-d-old progeny was increased by maternal pGH treatment
(P¼0·028), but was not altered by maternal feed (P¼0·47). Semi-
tendinosus muscle cross-sectional area was higher in progeny of
sows treated with 4 mg pGH/d than in progeny of sows treated with
0 mg pGH/d (P,0·05). The total number of muscle fibres per mm2
was higher (P¼0·011) in progeny of sows fed 3·0 kg/d than in
progeny of sows fed 2·2 kg/d in the second quarter of pregnancy,
but was not affected by maternal pGH treatment (P¼0·86).
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numbers of primary or secondary fibres per mm2 of muscle
cross-section, nor the secondary:primary fibres ratio in
semitendinosus muscle of progeny (Fig. 1, Table 3).
Higher maternal feed during the second quarter of preg-
nancy increased (P¼0·011) the total number of fibres per
mm2 (Fig. 1), the number of secondary fibres per mm2
(P¼0·008) and the secondary:primary fibre ratio
(P,0·0001) in semitendinosus muscle of progeny
(Table 3). Maternal feed during the second quarter of preg-
nancy did not alter semitendinosus cross-sectional area
(Fig. 1) or the number of primary fibres per mm2 (Table 3).
Co-variates of progeny semitendinosus muscle
measurements
Most (60 %) of the variance in cross-sectional area of semi-
tendinosus muscle in progeny was independently predicted
by current (61 d) progeny live weight (positive), with a
small positive effect of maternal plasma glucose during
treatment in pregnancy (Fig. 2). Most (58 %) of the vari-
ation in the density of primary muscle fibres (n per mm2
muscle cross-section) was independently predicted
(Table 4) by current progeny live weight (negative),
maternal plasma cholesterol (negative) and maternal
plasma non-esterified fatty acids (positive). About one-
third of the variance in secondary fibre density in progeny
muscle was independently predicted (Table 4) by maternal
weight on day 25 of pregnancy before treatments com-
menced (positive), and maternal plasma concentration of
IGF-II during treatment (negative). Similarly, 44 % of the
variance in total density (primary plus secondary) of fibres
in progeny semitendinosus muscle was independently pre-




































































































































































































































































































































































































































































































































































































































































































Fig. 2. Correlates of semitendinosus muscle cross-sectional area in
61-d-old progeny. For details of diets, treatments and procedures,
see Table 1 and p. 284. Semitendinosus muscle cross-sectional
area in 61-d-old progeny was predicted by multiple linear regression
equation: 2·94 þ (0·394 £ progeny weight at 61 d) þ (0·734 £
maternal glucose at day 40). The forward stepwise regression gave
an overall relationship of r 2 0·60, P,0·0001. Dr 2 for progeny
weight at 61 d was r 2 0·56, P,0·0001 and Dr 2 for maternal glucose
at day 40 of pregnancy was r 2 0·04, P¼0·046.









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Programming of progeny muscle in pregnancy 289
commenced (positive), maternal plasma IGF-II during
treatment (negative) and current (61 d) progeny live
weight (negative). About one-third of the variation in the
number of primary fibres:secondary fibres in progeny
muscle was independently predicted (Table 4) by progeny
abdominal circumference at birth (negative) and maternal
plasma cholesterol during treatments (negative).
Discussion
Increased feed availability and maternal pGH treatment in
the second quarter of pregnancy (from day 25 to 50) inde-
pendently altered semitendinosus muscle characteristics in
different ways in young female progeny postnatally.
Increased availability of maternal feed, i.e. reduced nutri-
tional restriction, during the second quarter of pregnancy
increased the density of secondary muscle fibres formed
in the semitendinosus muscle of progeny that were of
median birth weight for their litter, and hence increased
their total muscle fibre density and the secondary:primary
fibres ratio. Effects of maternal nutrition on progeny
muscle fibre density thus extend beyond the smallest
progeny of each litter, which have previously been
shown to be sensitive to increased maternal nutrition
during this period of pregnancy (Dwyer et al. 1994). We
have also demonstrated that progeny muscle fibre number
is more sensitive to maternal nutrition than shown
previously by Dwyer et al. (1994). In the present study,
the increase in maternal energy intake was smaller than
that given previously, we fed mothers only once per d,
and we investigated progeny of gilts, which might be
expected to have a greater nutrient demand for their own
growth than the third parity sows used by Dwyer et al.
(1994). Our present results confirm, however, that the
level of maternal nutrition prior to the period of fetal sec-
ondary muscle fibre formation can programme muscle
development in progeny. Because pigs with a higher secon-
dary:primary fibres ratio in their muscles have faster
growth rates and better feed-conversion efficiency during
the finisher period (Dwyer et al. 1993), increased maternal
nutrition during the second quarter of pregnancy in com-
mercially managed gilts is also likely to improve the
finisher performance of their progeny.
Maternal pGH treatment did not affect the fibre compo-
sition, but increased the cross-sectional area of semitendi-
nosus muscle in progeny of restricted-fed gilts. This
increase in muscle size is consistent with the findings of
Kelley et al. (1995) in well-fed gilts, where maternal
pGH treatment of gilts from day 28 to 40 of pregnancy
increased semitendinosus muscle weight and longissimus
dorsi cross-sectional area in 20 kg progeny. In the present
study, the increase in semitendinosus muscle cross-sec-
tional area in offspring following maternal treatment with
pGH must reflect either greater numbers of fibres per
muscle or an increase in non-fibre tissues such as perimy-
sial connective tissue within muscle, since pGH treatment
did not alter the density of fibres in muscle. Unlike admin-
istration of maternal GH earlier in pregnancy in mature
sows (day 10 to 24 or 27), which has been shown to
increase muscle fibre numbers and density in progeny at
birth (Rehfeldt et al. 1993, 1996), maternal GH treatment
of gilts in the second quarter of pregnancy did not alter
muscle fibre numbers of progeny. This suggests that pro-
geny muscle fibres are sensitive to maternal GH treatment
and maternal nutrition at different times during gestation.
Progeny muscle size responses to maternal pGH treatment
did not vary with maternal nutrition, further suggesting that
maternal GH treatment acts on progeny muscle develop-
ment through a different mechanism than does maternal
nutrition.
During the treatment period, increased maternal feed
intake (reduced nutritional restriction) increased maternal
weight gain, whilst treatment with pGH reduced maternal
fat. The maternal metabolic responses to pGH treatment
(increased concentrations of IGF-I, insulin, glucose and
non-esterified fatty acids and decreased concentrations of
urea in maternal plasma) were qualitatively similar to the
increases in insulin resistance and IGF-I expression and
decreases in lipogenesis and protein breakdown typical of
pGH treatment of non-pregnant pigs. In non-pregnant
pigs, the quantitative responses to pGH treatment vary
with development or age, genotype, gender, nutrition and
time (Owens et al. 1990; Klindt et al. 1995; Harrell et al.
1999). In previous studies in pregnant pigs maternal
plasma IGF-I concentrations of about 230–260mg (about
30–35 nmol/l)/l were attained in response to 1 week or
more of daily injections of pGH at doses of 26–33mg/kg
per d (Sterle et al. 1995; Gatford et al. 2000). In the present
study, maternal plasma IGF-I concentrations reached about
330mg (about 45 nmol)/l after 15 d treatment with pGH at
either 27 or 53mg/kg per d, suggest that the maximal IGF-I
response to pGH has been attained by a dose of about
25mg/kg per d. These results demonstrate that pregnancy
increases the sensitivity of plasma IGF-I in gilts to treat-
ment with pGH, compared with non-pregnant grower and
finisher pigs, where effective dose rates are typically
much greater than 50mg/kg per d (Owens et al. 1990;
Klindt et al. 1995; Harrell et al. 1999), and IGF-I responses
continue to increase with pGH doses up to 70mg/kg per d
(Etherton et al. 1987). The higher basal IGF-I levels in the
present study (about 210mg (30 nmol)/l) compared with
our previous study (about 75mg (10 nmol)/l; Gatford et al.
2000) may be due to the 20 % higher feed rate used in the
present study.
Consistent with other reports, increased maternal nutri-
tion (Dwyer et al. 1994) or pGH treatment (Kelley et al.
1995) during the second quarter of pregnancy did not
increase weight of progeny at birth. We have, however, pre-
viously shown that treatment with pGH at doses similar to
the lower dose used in the present study increases fetal body
weight by about 15 % at day 51 of gestation on a plane of
nutrition 20 % lower than that used here (Gatford et al.
2000). This implies that any gain in fetal weight in response
to pGH (and possibly nutrition) during the treatment period
is lost later in gestation due to maternal constraint of fetal
growth. In the present study, increased maternal nutrition,
but not pGH treatment, from day 25 to 50 of pregnancy
increased progeny growth rate during lactation (birth to
27 d postnatally). Piglet demand is a major determinant of
sow milk production, particularly in early lactation (Auldist
& King, 1995). Hence, the increased progeny growth-rate
during lactation suggests that increased maternal nutrition
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in the second quarter of pregnancy increases the neonatal
appetite of progeny and improves their ability to recover
from maternal constraint in late gestation. Consistent with
programming of appetite regulation, increased maternal
nutrition at this stage of pregnancy also increases the
plasma concentrations of leptin in 61-d-old progeny
(Ekert et al. 2000). It is also possible that better nutrition
in early pregnancy has improved maternal capacity for
milk production in lactation.
The mechanisms by which nutrition and pGH treatment
during pregnancy prior to the development of secondary
fibres in the fetus programme muscle characteristics in
postnatal offspring are not known. Increased feed avail-
ability to the mothers may increase the growth and diam-
eter of primary fibres in their fetuses, which occurs
during the treatment period, thereby providing a greater
surface area for subsequent development of secondary
muscle fibres (Wigmore & Stickland, 1983). Alternatively,
improved fetal nutrition during the treatment period might
accelerate development of fetal endocrine systems, such as
the IGF axis (Owens et al. 1994; Kind et al. 1995; Sterle
et al. 1995), which promotes fetal muscle growth (Lok
et al. 1996) and differentiation of the myoblasts that will
form secondary fibres (Dwyer et al. 1994). It is also poss-
ible that the changes in muscle phenotype in adolescent
progeny are secondary consequences of effects of treat-
ments relatively early in pregnancy on developmental pro-
cesses that occur either later in pregnancy or in the earlier
postnatal life of progeny. Therefore, measurements of
mothers and offspring were made before, during and
after treatment so that covariates of muscle phenotype in
adolescent progeny might be identified. These included
maternal and progeny growth, as well as maternal plasma
concentrations of hormones and metabolites that may influ-
ence the fetal environment. Interpretation of the plasma
measurements is restricted somewhat because these were
made in a specimen collected from each mother on a
single occasion during treatment in pregnancy. In particu-
lar, the concentrations of insulin and the metabolites can
fluctuate rapidly, so their utility as covariates is relatively
weak. This is less of a problem for IGF-I and -II as stabil-
isation by association with IGF-binding proteins means
that temporal variations in their concentrations in blood
are small (Owens et al. 1991).
Neither of the maternal treatments affected the density
of primary fibres (n per mm2 transverse sectional area) in
progeny muscle. Most of the variation in primary fibre
density could be explained by variation in the live
weight of progeny at the time of collection of the muscle
specimen (24 %), combined with variation in the concen-
trations of cholesterol (23 %) and non-esterified fatty
acids (12 %) found in maternal blood during treatment in
pregnancy. These independent covariates together
accounted for 58 % of the variation in primary fibre density
in muscle. Given the strong correlations between maternal
plasma cholesterol and lactate and between maternal
plasma non-esterified fatty acids and glucose during the
treatment period, these relationships probably do not
directly reflect the mechanisms which determine primary
muscle fibre density, but do suggest that the metabolic
state of the mother during treatment in pregnancy is the
major prospective determinant of primary muscle fibre
density in postnatal progeny.
Feed availability, but not pGH treatment, in the second
quarter of pregnancy increased the density of secondary
fibres, the total (primary plus secondary) density of
fibres and the secondary:primary fibre ratio in semitendi-
nosus muscle of adolescent progeny. However, maternal
nutrition did not alter any of the covariates of secondary
or total muscle fibre density (maternal live weight at
day 25 of pregnancy, maternal plasma IGF-II concen-
trations during treatment and progeny body-weight at
61 d of age), implying that these factors are not involved
in the mechanism by which increased feed availability
in the second quarter of pregnancy increases secondary
and total fibre density in semitendinosus muscle of adoles-
cent offspring. Although maternal nutrition increased both
maternal cholesterol during pregnancy and the secondary:
primary fibres ratio in postnatal progeny, maternal pGH
treatment also increased maternal cholesterol but did not
alter the ratio of fibre types in postnatal progeny, implying
that increased maternal cholesterol is not a mechanism for
the effects of these treatments on muscle fibre compo-
sition. The association between muscle fibre density and
later progeny weight is consistent with higher growth
potential in animals with more muscle fibres, as shown
previously in older animals (Dwyer et al. 1993). The posi-
tive associations between maternal size prior to treatment,
and total and secondary fibre density in progeny semiten-
dinosus muscle at 61 d of age are consistent with the
degree of maternal constraint of fetal growth during for-
mation of secondary muscle fibres affecting their develop-
ment, since larger gilts are likely to have more energy
reserves to support fetal growth. In addition, these studies
were conducted in a commercial population that has very
low genetic heterogeneity, so heavier gilts are probably
also slightly more mature than lighter gilts and will
have slightly less nutrient demand for maternal growth
during pregnancy. Nutritional manipulations that increase
maternal growth in adolescent sheep compromise growth
of their placenta and fetus (Wallace et al. 1996), and
fetal muscle growth is reduced in conjunction with
increased maternal muscle and fat deposition in the ado-
lescent sheep (Palmer et al. 1998). The association
between the concentrations of IGF-II in maternal blood
at the end of the first third of pregnancy and the density
of muscle fibres in adolescent progeny suggests a novel
potential role for maternal IGF-II during pregnancy in
an intra-uterine programming mechanism. Studies of
mice that are deficient in IGF-II due to mutation of the
Igf2 gene show that this growth factor is essential for pla-
cental development (Graves, 1998). In addition, we
recently observed that the concentrations of endogenous
IGF-II in the blood of pregnant guinea-pigs are related
to histological markers of placental development and
transport capacity (Roberts et al. 2001), and have also
shown that treatment of pregnant guinea-pigs with IGF-
II increases placental weight (Sohlstrom et al. 2001).
Therefore it is possible that IGF-II in the maternal circu-
lation has actions that improve the ability of the placenta
to transfer nutrients to the fetus that are important for
muscle development.
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Maternal pGH treatment increased both progeny semiten-
dinosus cross-sectional area and maternal plasma glucose at
day 40 of pregnancy, and maternal plasma glucose was a
positive but weak covariate of semitendinosus cross-sec-
tional area. Increased maternal glucose may partly mediate
the effect of maternal pGH treatment on muscle growth,
although the increase in maternal glucose in response to
maternal GH treatment was not sufficient to account for
the observed increase in semitendinosus cross-sectional
area in progeny, suggesting that maternal pGH treatment
also increases muscle cross-sectional area by glucose-
independent mechanisms. Direct infusion of glucose into
pregnant gilts and examination of muscle characteristics
in their progeny would clarify the role of glucose in
programming of muscle.
In conclusion, maternal pGH treatment and increased
nutrition during the second quarter of pregnancy in
feed-restricted gilts differentially affect the size and fibre
composition of progeny semitendinosus muscle. The mech-
anisms for programming of muscle fibre types by an
altered maternal environment may involve endocrine
IGF-II in the mother and require further investigation.
Increased maternal plasma glucose may partially account
for the increase in progeny semitendinosus cross-sectional
area in response to maternal pGH treatment.
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